BioNTech CEO Ugur Sahin (Photo by ddp images/Sipa USA)
BioNTech and Pfizer announce $225M shingles vaccine project, offering mRNA challenger to GlaxoSmithKline's Shingrix
One of the biggest storylines of biotech’s next half-decade will be where Moderna, BioNTech and their growing list of rivals push the mRNA technology that’ …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
